Another Partnership between Immunocore and MedImmune against Skin Cancer
Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases,…
As one of the leading causes of death worldwide, cancer receives great focus from the life sciences industry. Indeed, it’s the largest therapeutic focus area for biotech and pharma companies, which are working on a large number of therapeutic approaches, including small molecules, T cell therapies, and antibody therapies.
Global cancer drug sales are estimated to reach €221B by 2024. The top 10 blockbuster drugs are sold by big pharma companies, like Roche, Merck, AbbVie, and Bristol-Myers Squibb. Examples of blockbusters include Keytruda, Rituxan, and Herceptin.
Biotech companies are doing a fair bit of the work as well. Read on to keep up to date with the latest oncology research, discoveries, and market developments.
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportImmunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases,…
Merck Serono appointed Dr. Alise Reicin as Senior Vice President, Head of Global Clinical Development.…
Just a week after announcing its intention to launch an IPO in the United States,…
After successfully complete phase I clinical study, apceth initiates the Phase II of world’s first…
Epigenomics, the German-American cancer molecular diagnostics company, completed the enrollment for its ADMIT trial (AD herence…
Rigontec has raised €4.8M in the second closing of its Series A financing round from Forbion…
New Oncology completed a financing round to prepare the market launch of NEOliquid, a non-invasive…
Today, it has been accepted! The first drug approved through the Early Access to Medicine Scheme…
Created in 2012 by Emile Loria and Dominique Costantini, OSE Pharma is a European cancer…
MorphoSys AG and Emergent BioSolutions will initiate a Phase I clinical study to evaluate the…
Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint…
Bristol-Myers Squibb signs an exclusive agreement with Bavarian Nordic for PROSTVAC, a prostate-specific antigen-targeting cancer…